Rozales Franciéli P, Ribeiro Vanessa B, Magagnin Cibele M, Pagano Mariana, Lutz Larissa, Falci Diego R, Machado Adão, Barth Afonso L, Zavascki Alexandre P
Programa de Pós Graduação em Ciências Farmacêutica, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; Laboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil.
Laboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil; Programa de Pós Graduação em Ciências Médicas, Faculdade de Medicina, UFRGS, Porto Alegre, Brazil.
Int J Infect Dis. 2014 Aug;25:79-81. doi: 10.1016/j.ijid.2014.01.005. Epub 2014 May 21.
To evaluate the emergence of New Delhi metallo-β-lactamase 1 (NDM-1)-producing Enterobacteriaceae isolates in Brazil.
From April to October 2013, following the detection of the first NDM-1-producing isolate, a surveillance study was performed for the detection of blaNDM-1 among Enterobacteriaceae isolates with reduced susceptibility to carbapenems in 17 hospitals of Porto Alegre, Brazil. Real-time PCR was used to determine the presence of carbapenemase genes, which were further sequenced. Clonal relatedness was assessed by pulsed-field gel electrophoresis (PFGE).
A total of 1134 isolates were evaluated. blaNDM-1 was detected in 11 (0.97%) isolates: nine Enterobacter cloacae complex (eight belonging to a single clone recovered from two distinct hospitals and the other strain from a third hospital) and two Morganella morganii (belonging to a single clone recovered from one hospital). Most isolates presented high-level resistance to carbapenems.
NDM-1-producing Enterobacteriaceae have emerged rapidly in the hospitals of the Brazilian city where they were first detected. The emergence of NDM-1 in Brazil is of great concern, since it is a severe threat to antimicrobial therapy against Enterobacteriaceae in this country.
评估巴西产新德里金属β-内酰胺酶1(NDM-1)的肠杆菌科分离株的出现情况。
2013年4月至10月,在检测到首例产NDM-1的分离株后,对巴西阿雷格里港17家医院中对碳青霉烯类药物敏感性降低的肠杆菌科分离株进行了blaNDM-1检测的监测研究。采用实时PCR确定碳青霉烯酶基因的存在,并进一步测序。通过脉冲场凝胶电泳(PFGE)评估克隆相关性。
共评估了1134株分离株。在11株(0.97%)分离株中检测到blaNDM-1:9株阴沟肠杆菌复合体(8株属于从两家不同医院分离出的单个克隆,另一株来自第三家医院)和2株摩根氏摩根菌(属于从一家医院分离出的单个克隆)。大多数分离株对碳青霉烯类药物呈现高水平耐药。
产NDM-1的肠杆菌科细菌在巴西首次检测到的城市的医院中迅速出现。NDM-1在巴西的出现令人高度关注,因为它对该国针对肠杆菌科细菌的抗菌治疗构成严重威胁。